Treatment and Coronavirus (COVID-19)
is an infectious respiratory disease caused by SARS-CoV-2, previously
referred to as "2019 novel coronavirus."1
Lilly and Company has not studied the use of ramucirumab in patients
with COVID-19 nor specifically in patients at risk of contracting
Risk and Benefit Considerations
physicians should assess the patient’s individual benefit/risk
ratio considering the patient's signs and symptoms, prior medical
history, concomitant medications, and other individual factors when
making ramucirumab treatment decisions in the context of COVID-19.
Ramucirumab dose adjustments, made at the physician’s
discretion, should follow the label. Supportive treatment should be
provided as clinically indicated and patients monitored
appropriately. Drug interactions between ramucirumab and potential
COVID-19 treatments should be considered and are described below.2
following medications are not expected to have a clinically relevant
effect on ramucirumab exposure and ramucirumab is not expected to
have a clinically relevant effect on the exposure of the following
Disease Resources for COVID-19
the most current information regarding COVID-19, please refer to the
Naming the coronavirus disease (COVID-19) and the virus that causes
it. World Health Organization. Accessed March 17, 2020.
Data on file, Eli Lilly and Company and/or one of its subsidiaries.
Coronavirus disease (COVID-19) outbreak. World Health Organization
Europe. Accessed March 20, 2020.
COVID-19. European Centre for Disease Prevention and Control.
Accessed March 20, 2020.
European Society for Medical Oncology. Accessed March 23th.
[NICE] National Institute for Health and Care Excellence.
Coronavirus (COVID-19). Available from:
Accessed 25 March 2020.
= Centers for Disease Control and Prevention
= coronavirus disease 2019
= National Comprehensive Cancer Network
= severe acute respiratory syndrome coronavirus 2
= World Health Organization